---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000045"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:32:07.496686+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics discontinues part two of GeneSight study; control group deemed unreliable

## Summary
- Part one (April 2024) showed 29% drop in all-cause hospitalizations and 39% drop in psychiatric-related hospitalizations 180 days post-GeneSight.
- Part two aimed to compare GeneSight patients vs. matched non-GeneSight control; significant baseline disparities made control group non-viable.
- Company concluded data comparing the two groups were not reliable and halted the analysis.
- GeneSight's causal role in hospitalization reduction remains unconfirmed without a valid control group.
- Company plans to publish full part one results in the near future.

## SEC filing metadata
- accession: 0000899923-24-000045
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000045/0000899923-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000045/mygn-20240904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000045
- JSON: https://secwatch.observer/filing/0000899923-24-000045.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.